RemedyRepack Ketorolac Injection Recall: Visible Particulate Risk
RemedyRepack recalls Ketorolac 30 mg/mL injections with visible crystalline particles that could cause serious injury if injected.
Use caution until it’s fixed
Crystallization: Product is being recalled due to the manufacturer's recall due to the presence of visible particulate in vials that has been identified as crystalline ketorolac calcium salt.
Contact the company
What happened, in plain English
RemedyRepack is recalling Ketorolac Trom 30 mg/mL injections that contain visible crystalline particles. This could cause serious injury if the medication is injected. Read more at govinfonow.com/recall/41349-remedyrepack-ketorolac-injection-recall-visible-particulate-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/41349-remedyrepack-ketorolac-injection-recall-visible-particulate-risk · Updated October 7, 2026 · FDA enforcement record: FDA #D-1176-2017
Cite this page
“RemedyRepack Ketorolac Injection Recall: Visible Particulate Risk.” GovInfoNow, updated October 7, 2026. https://govinfonow.com/recall/41349-remedyrepack-ketorolac-injection-recall-visible-particulate-risk. Based on FDA recall #D-1176-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1176-2017%22&limit=1).
Why it’s dangerous
The injections contain visible crystalline ketorolac calcium salt particles. These particles could cause serious injury if injected into the body, as they may clog blood vessels or cause tissue damage.
Who’s affected
Patients prescribed Ketorolac injections by doctors who received these specific vials are affected. Those with the recalled vials are at risk of serious injury if the medication is administered.
How to tell if you have this one
Check for vials labeled with NDC 61786-0741-01 (1 mL vials) or NDC 61786-0741-08 (10 x 1 mL vials per tray). The product was manufactured by Amphastar in Rancho Cucamonga, California.
- Brand
RemedyRepack- Category
Drug
What to do — step by step
Check Vial Labels
Look for NDC codes 61786-0741-01 or 61786-0741-08 on the vial packaging.
Where it went and when
Where it was distributed
Distributed in Louisiana.
FDA distribution: “Product was distributed to one consignee in Louisiana.” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Louisiana.
Recall timeline
FDA terminated this recall 4 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1176-2017 (August 22, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1176-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 7, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.